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Abstract Our current clinical approach to visual hallu-
cinations is largely derived from work carried out by Ge-
orges de Morsier in the 1930s. Now, almost a century after
his influential papers, we have the research tools to further
explore the ideas he put forward. In this review, we address
de Morsier’s proposal that visual hallucinations in all
clinical conditions have a similar neurological mechanism
by comparing structural imaging studies of susceptibility to
visual hallucinations in Parkinson’s disease, Alzheimer’s
disease, Dementia with Lewy bodies and schizophrenia.
Systematic review of the literature was undertaken using
PubMed searches. A total of 18 studies across conditions
were identified reporting grey matter differences between
patients with and without visual hallucinations. Grey
matter changes were categorised into brain regions relevant
to current theories of visual hallucinations. The distribution
of cortical atrophy supports de Morsier’s premise that vi-
sual hallucinations are invariably linked to aberrant activity
within visual thalamo-cortical networks. Further work is
required to determine by what mechanism these networks
become predisposed to spontaneous activation, and whe-
ther the frontal lobe and hippocampal changes identified
are present in all conditions. The findings have implications
for the development of effective treatments for visual
hallucinations.
Keywords Parkinson’s disease  Alzheimer’s disease 
Dementia with Lewy bodies  Schizophrenia  MRI 
Structural imaging  Grey matter
Introduction
In 1930, Georges de Morsier published a critique of the
widely accepted psychodynamic account of hallucinations,
suggesting instead they be considered as neurological
symptoms [1]. He had been studying in Paris under de
Cle´rambault who, influenced by studies of epilepsy, de-
veloped a theory of psychosis in which its constituent
features were caused by aberrant neural activity within
specific brain networks leading to psychopathological
symptoms (mental automatisms) [2]. Central to this view
was the assumption that the location of the aberrant circuit
for a given symptom was invariant across clinical condi-
tions. de Morsier went on to apply these ideas to visual
hallucinations—visual automatisms in his terms—review-
ing their similarity across neurological and psychiatric
contexts as evidence for a mechanistic cause.
….existe-t-il une diffe´rence entre les automatismes ou
hallucinations visuelles accompagnant les syndromes
neurologiques…..et les automatismes ou hallucina-
tions visuelles qu’on rencontre dans les psychoses
hallucinatoires chroniques? Nous sommes fonde´s a`
re´pondre qu’il n’en existe aucune. Les unes comme les
autres peuvent avoir les meˆmes caracte`res et appa-
raissent de fac¸on semblable parce que les unes comme
les autres sont d’origine strictement me´canique [3].
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(…is there a difference between automatisms or visual
hallucinations accompanying neurological syn-
dromes…and automatisms or visual hallucinations
encountered in chronic hallucinatory psychosis? We
are led to reply that there is none. One like the other
can have the same features and appear in a similar way
because one like the other is of strictly mechanical
origin).
For de Morsier, apart from rare visual hallucinations
associated with one or other eye which he linked to anterior
visual pathways, the predominant underlying cause of vi-
sual hallucinations was aberrant activity in thalamo-corti-
cal networks connecting either the lateral geniculate
nucleus to primary visual cortex or pulvinar to partieto-
occipital cortex (Fig. 1) [3, 4]. Yet, while confident about
the brain location of this aberrant activity, he recognised
that research techniques were not yet available to investi-
gate their underlying neurophysiology [1].
Now, approaching a century after these ideas were first
formulated, we have the research tools to begin to address
them. At one level, de Morsier seems to have been correct.
Based on the evidence of functional imaging, at the time a
visual hallucination is experienced spontaneous ‘aberrant’
increases in activity occur within the visual system. This is
the case, irrespective of whether the hallucination occurs
in the context of eye disease [5] or schizophrenia/first
episode psychosis [6, 7]. Note that a recent case study of
Parkinson’s disease found suppression of activity in visual
cortex at the time of visual hallucinations [8] which, if
replicated, would point to a variation in underlying neu-
rophysiology. However, even if activity increases turn out
to be the rule, the functional imaging evidence only cap-
tures the end point of a longer causal chain. There are
likely to be many different ways in which a given region
of cortex becomes susceptible to spontaneous ‘aberrant’
activity. It might, for example, result from alterations in
intra-cortical connections within a cortical region. Alter-
natively, it might result from changes in connectivity
across a wider cortical and subcortical network. This
deeper level of understanding of the neurophysiological
cause of visual hallucinations was purely of academic in-
terest for de Morsier as there were limited options for
treatment. Today, the question of what predisposes a re-
gion of cortex to spontaneous activity and visual halluci-
nations is central to our understanding of how to treat them
as different types of predisposing mechanism are likely to
require different treatment approaches. de Morsier’s
unanswered neurophysiological question might therefore
be reformulated in the era of neuroimaging into one of
whether the same changes in cortical networks are found
in patients susceptible to visual hallucinations, irrespective
of the clinical condition in which they occur.
Fig. 1 The anatomical pathways linked to visual hallucinations as
proposed by de Morsier. Hallucinations seen in both eyes were linked
to thalamo-cortical networks connecting either the lateral geniculate
nucleus and primary visual cortex or pulvinar and partieto-occipital
cortex (b). Hallucinations seen in one eye were linked to the anterior
visual pathways (a). Adapted from [4]
J Neurol (2015) 262:1780–1790 1781
123
In this review, we address this issue by comparing
structural imaging studies of susceptibility to visual hal-
lucinations in Parkinson’s disease, Alzheimer’s disease,
Dementia with Lewy bodies, schizophrenia and eye disease
(Charles Bonnet Syndrome). We focus on studies reporting
grey matter differences between patients with and without
visual hallucinations as the limited number of white matter,
tractography and functional activation studies limits com-
parison across conditions. Most of the studies reviewed do
not provide detailed cortical locations, limiting us to a
qualitative summary in which we divide the brain into re-
gions defined by their hypothesised role in current accounts
of visual hallucinations.
Methods
The imaging studies were identified from citations in
expert reviews and PubMed searches using combinations
of keywords ‘visual hallucinations’, ‘structural imaging’
and ‘MRI’ for each of the conditions. After excluding
studies of visual hallucinations in the context of delirium
or a single occurrence, a total of 18 studies were identified
reporting grey matter differences between patients with
and without visual hallucinations. The grey matter chan-
ges reported in each study were categorised into (i) oc-
cipital cortex including primary visual cortex (grey matter
changes encompassing calcarine cortex on the medial
occipital lobe) and visual association cortex (regions in
the lateral, ventral and dorsal occipital lobe); (ii) superior
and inferior parietal lobules to include the dorsal visual
pathway, parietal eye fields and supra-marginal gyrus; (iii)
the temporal lobe to include the ventral visual pathway
and hippocampus; (iv) the frontal lobe to include dorso-
lateral prefrontal cortex, frontal pole, frontal eye fields
and supplementary eye fields; (v) subcortical regions in-
cluding the thalamus and basal ganglia. Where studies did
not provide stereotaxic coordinates we used figures and
text descriptions to categorise the activity into these
regions.
Parkinson’s disease
Visual hallucinations are the most common hallucination
modality in Parkinson’s disease occurring in approximately
22–38 % of clinic-based samples [9]. The occurrence of
visual hallucinations in patients with Parkinson’s disease is
associated with worse outcome, including nursing home
placement [10], increased morbidity and mortality [11] and
cognitive decline [12, 13]. Typically, visual hallucinations
are of animals, people or objects [14], begin in the second
half of the disease, are persistent and get progressively
worse [15].
Methodological considerations
As cognitive decline and visual hallucinations are linked
in Parkinson’s disease, cognition needs to be controlled
for when comparing patients with and without visual
hallucinations. Although hallucinations and illusions in
the visual modality are more common than other senses
[16], patients with visual hallucinations may also expe-
rience auditory hallucinations, delusions and lack in-
sight. These symptoms are themselves associated with
cortical changes so that a change identified in a given
cortical area might not be linked specifically to visual
hallucinations. We did not differentiate studies reporting
Parkinson’s disease at different stages of cognitive de-
cline (Parkinson’s disease and Parkinson’s disease de-
mentia) but report studies of Dementia with Lewy bodies
in a separate section.
Structural imaging findings
Ramirez-Ruiz et al. [17]—Parkinson’s disease patients
with (N = 18) and without visual hallucinations (N = 20)
and healthy controls (N = 21). They found grey matter
volume loss bilaterally in lateral occipital regions and the
parietal lobe when compared to patients without visual
hallucinations and frontal regions when compared to
healthy controls.
Ibarretxe-Bilbao et al. [18]—Three groups of patients
with Parkinson’s disease: (i) with dementia (N = 9), (ii)
without dementia but with visual hallucinations (N = 16)
and (iii) without dementia or visual hallucinations
(N = 19). Using a region of interest approach, they found
volume differences in the hippocampus. Non-demented
Parkinson’s disease patients with visual hallucinations
showed hippocampal atrophy restricted to the hippocam-
pal head compared to those without visual hallucinations.
By contrast, the Parkinson’s disease dementia patients
demonstrated diffuse hippocampal atrophy compared to
those without dementia or visual hallucinations. The au-
thors hypothesised that hippocampal involvement begins
in the head, where it results in visual hallucinations, and
then spreads to the tail where it results in additional
memory impairment. To test this hypothesis, the same
group performed a 30-month follow-up study (12 patients
with Parkinson’s disease and visual hallucinations, 14
patients with Parkinson disease without visual hallucina-
tions and 12 healthy controls) [19]. At follow-up, 9 of the
12 visual hallucinators had gone on to develop dementia.
Comparing their baseline and follow-up scans, the visual
hallucinators had greater grey matter loss in bilateral
parietal cortex (predominantly precuneus and supra-mar-
ginal gyrus), insula, superior and inferior temporal gyrus,
superior and inferior frontal gyrus, anterior and posterior
1782 J Neurol (2015) 262:1780–1790
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cingulate gyrus, thalamus and limbic areas including
hippocampus. Patients with Parkinson’s disease without
visual hallucinations at baseline did not exhibit the same
pattern of atrophy at follow-up and none had developed
dementia.
Sanchez-Castaneda et al. [20]—Parkinson disease pa-
tients with dementia and visual hallucinations (N = 7)
compared to those without hallucinations (N = 8). They
found reduced grey matter in the left lateral orbitofrontal
cortex.
Meppelink et al. [21]—Parkinson’s disease patients with
visual hallucinations (N = 11) compared to those without
hallucinations (N = 13). Although they identified grey
matter reductions bilaterally in prefrontal and parietal
cortices in both groups compared to healthy controls
(N = 14), they did not find significant differences in grey
matter between patients with and without visual
hallucinations.
Watanabe et al. [22]—Parkinson’s disease without de-
mentia with (N = 13) and without visual hallucinations
(N = 13). Visual hallucinations were associated with re-
duced volume in bilateral occipital regions, right supra-
marginal gyrus and left fusiform gyrus, bilateral
dorsolateral prefrontal cortex, frontal pole and the middle
portion of the left cingulate gyrus.
Goldman et al. [23]—Parkinson’s disease with visual
hallucinations (N = 25, 6 of whom also had auditory
hallucinations) compared to Parkinson’s disease without
visual hallucinations (N = 25). Within apriori regions of
interest, they found that visual hallucinations were asso-
ciated with reduced grey matter volume, bilaterally in the
cuneus, fusiform gyrus, lateral occipital cortex, inferior
parietal lobule, cingulate and precentral gyrus as well as
regions in the right lingual gyrus and left paracentral
gyrus.
Gama et al. [24]—Parkinson disease (N = 39) and
healthy controls (N = 10). The Parkinson’s disease group
was divided into visual hallucinators (N = 11) and non-
hallucinators (N = 28). Using a region of interest ap-
proach, they found that visual hallucinators had reduced
grey matter volume in the left opercular frontal gyrus and
left superior frontal gyrus compared to healthy controls.
Dementia with Lewy bodies
Dementia with Lewy bodies accounts for up to 30.5 % of
all dementia cases [25]. Visual hallucinations are one of the
core features of Dementia with Lewy bodies along with
fluctuating consciousness and a movement disorder [25–
27]. The prevalence of visual hallucinations in patients
with Dementia with Lewy bodies may be as high as 80 %,
typically of people or animals.
Methodological considerations
The high prevalence of visual hallucinations and their in-
clusion in the diagnostic criteria mean that it is difficult to
compare patients with and without visual hallucinations in
this condition. Most studies have compared patients with
Dementia with Lewy bodies to another condition, for ex-
ample, Alzheimer’s disease, while matching for cognitive
impairment. Where visual hallucinations are not the primary
research question, patient hallucination status may not be
reported. As in Parkinson’s disease, patients with Dementia
with Lewy bodies may experience hallucinations in other
modalities, delusions and lack of insight. Cortical differ-
ences identified in studies of Dementia with Lewy bodies
may thus be attributable to visual hallucinations, associated
symptoms or the clinical condition used as control.
Structural imaging findings
Sanchez-Castaneda et al. [20]—Dementia with Lewy
bodies with visual hallucinations (N = 6) compared to
Dementia with Lewy bodies without visual hallucinations
(N = 6). Using a region of interest analysis, they found
that patients with Dementia with Lewy bodies and visual
hallucinations had reduced grey matter volume in the right
inferior frontal gyrus. They also found an association be-
tween the severity of visual hallucinations in Dementia
with Lewy bodies and grey matter volume reduction in the
right inferior frontal gyrus and left precuneus. Occipital,
parietal and temporal lobe regions were included in the
analysis but were not found to be significantly different
between the two groups.
Middlekoop et al. [28]—Dementia with Lewy bodies
with (N = 20) and without (N = 3) visual hallucinations.
They did not find significant differences in occipital lobe
volume (controlling for whole-brain volume) in an analysis
of variance (ANOVA) model combining patients with
Alzheimer’s disease (see below). The trend difference be-
tween Dementia with Lewy bodies patients with and
without visual hallucinations was in the opposite direction
to that reported in other studies with a larger occipital
volume in hallucinators than non-hallucinators.
Beyer et al. [29]—Dementia with Lewy bodies with
unspecified visual hallucination status (N = 18) compared
to Parkinson’s disease dementia with unspecified visual
hallucination status (N = 15). Cortical atrophy was more
pronounced in the Dementia with Lewy bodies group in
occipital, temporal (including hippocampus and amygdala)
and parietal cortices.
Josephs et al. [30]—Patients with posterior cerebral at-
rophy and visual hallucinations (N = 7 scanned) compared
to those without visual hallucinations (N = 7 scanned) and
J Neurol (2015) 262:1780–1790 1783
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healthy controls (N = 38). Compared to controls, bilateral
grey matter atrophy was found in the basal forebrain, tha-
lamus, hypothalamus and basal ganglia in visual halluci-
nators. These changes were not found in the group without
visual hallucinations compared to controls. Both groups
with and without visual hallucinations had atrophy in the
primary visual cortex and midbrain compared to controls;
however, the atrophy was more pronounced in the visual
hallucinator group. Including patients that did not par-
ticipate in the scanning study, 10 of 13 patients with visual
hallucinations had features of parkinsonism, 6 had my-
oclonus and 8 had a rapid eye movement sleep disorder. At
follow-up ([2 years), all 13 patients in this group met cri-
teria for a diagnosis of Dementia with Lewy Bodies.
Whitwell et al. [31]—Dementia with Lewy bodies
(N = 72, 62.5 % with visual hallucinations) compared to
matched Alzheimer’s patients (N = 72) and normal con-
trols (N = 72). Compared to normal controls, grey matter
loss was identified in the dorsal midbrain, posterior hip-
pocampus, insula, frontal and parietal lobes and sur-
rounding the third ventricle. No regions were more
atrophied in the Dementia with Lewy bodies group than the
Alzheimer’s disease group on whole-brain analysis; how-
ever, a pre-defined region of interest in the dorsal midbrain
had greater atrophy in the Dementia with Lewy bodies
group.
Delli Pizzi et al. [32]—Dementia with Lewy bodies and
visual hallucinations (N = 18) compared to Alzheimer’s
disease without hallucinations (N = 15) and age-matched
healthy controls (N = 14). Dementia with Lewy bodies
was associated with reduced cortical thickness bilaterally
in the pericalcarine cortex, lingual gyrus, cuneus, pre-
cuneus and superior parietal gyrus. The cortical thinning in
the right hemisphere precuneus and superior parietal gyrus
was correlated with hallucination severity.
Alzheimer’s disease
Visual hallucinations are the most common hallucination
modality in patients with Alzheimer’s disease with an es-
timated prevalence of 13 % [33]. Alongside other psy-
chotic features in Alzheimer’s disease, they precipitate
admission to psychiatric hospitals and nursing home
placement [34]. As with Parkinson’s disease, they are
linked to more rapid cognitive decline and worse overall
prognosis [35]. In Alzheimer’s disease, patients typically
hallucinate people, animals, insects and objects [36].
Methodological issues
As for Parkinson’s disease and Dementia with Lewy bodies,
visual hallucinations are the commonest modality halluci-
nated. However, as in these conditions, visual hallucinations
co-occur with other modalities, delusions and loss of insight
and are associated with greater cognitive decline, all of
which may contribute to the cortical changes identified.
Structural imaging findings
Holroyd et al. [37]—Alzheimer’s disease with (N = 7) and
without (N = 7) visual hallucinations, matched for cogni-
tive score. They found that patients with visual hallucina-
tions had significantly smaller occipital lobes, controlling
for whole-brain volume.
Middlekoop et al. [28]—Alzheimer’s disease with
(N = 3) and without (N = 22) visual hallucinations. They
did not find significant differences in occipital lobe volume
(controlling for whole-brain volume) in an ANOVA model
which included the Dementia with Lewy bodies group
described above. As with Dementia with Lewy bodies, the
trend found was in the opposite direction to that expected,
with larger occipital volume in hallucinators compared to
non-hallucinators.
Donovan et al. [38]—A longitudinal study over 3 years
of changes in cognition (Cohort N = 812, Alzheimer’s
disease at baseline N = 188). Although the modality of
hallucinations was not specified, they are likely to have
been predominantly visual, based on previous prevalence
studies. They found reduced lateral parietal cortical thick-
ness predicted increasing hallucinations but not occipital
(lingual gyrus), frontal (including dorsolateral prefrontal
cortex), inferior temporal or superior parietal cortex.
Schizophrenia
Unlike the conditions reviewed above, in schizophrenia,
visual hallucinations are less prevalent than auditory verbal
hallucinations. The weighted mean point prevalence of vi-
sual hallucinations in a recent meta-analysis was 27 %
(range of 4–65 %) with that of auditory hallucinations 59 %
(range 25–86 %) [39]. Patients with visual hallucinations
invariably experience hallucinations in other modalities,
either at the same time or on different occasions [40]. In
schizophrenia, visual hallucinations are associated with
poorer prognosis [41] and are typically people, faces, ani-
mals, objects or events (e.g. visions of fires) and frightening
[39].
Methodological issues
The fact that visual hallucinations in schizophrenia never
occur in isolation influences the choice of control group and
the inferences that can be drawn. One approach is to
use schizophrenia patientswith auditory verbal hallucinations
but without visual hallucinations. The disadvantage is that
regions involved in both hallucination modalities will not be
1784 J Neurol (2015) 262:1780–1790
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identified in this type of analysis. Another approach is to use
patients with schizophrenia but without hallucinations. This
will identify all regions associated with hallucinations but is
unable to link a given cortical region with one or other mod-
ality. Comparison with healthy controls has the additional
problem of confounding changes related to schizophrenia.
Structural imaging findings
Jardri et al. [7]—Adolescent patients with first episode
psychosis, a prodromal state that may or may not progress
to schizophrenia (N = 20). Compared to healthy controls,
they found a decrease in cortical thickness in visual and
auditory association cortex but not in primary visual or
auditory cortex.
Amad et al. [42]—Two subgroups of patients with
schizophrenia: (i) with auditory hallucinations (N = 17)
and (ii) with auditory and visual hallucinations (N = 16).
Using a region of interest analysis, they found that hip-
pocampal mean volumes were increased in the auditory
and visual hallucinator group, with bilateral hypertrophy of
the anterior and posterior end of CA1 and subiculum. It
was hypothesised that these changes were due to plastic
modification of the hippocampus related to changes in
hippocampal connectivity found in the same study.
Cachia et al. [43]—Same design as Amad et al. [42] using
a mathematical descriptor of gyral architecture, an index of
early cortical development. They reported decreased gyral
folding in the right hemisphere as a whole in patients with
auditory and visual hallucinations. Using a region of interest
analysis, decreased gyral folding was also found in right
superior parietal cortex and the left sylvian fissure.
Charles Bonnet syndrome
Charles Bonnet syndrome describes the association of visual
hallucinations and eye disease, occurring in*10 % of people
with eye disease [44, 45] (range 0.4 % [46]—63 % [47]). The
main risk factor for developing Charles Bonnet Syndrome is a
reduction in visual acuity [45]. The most common type of
visual hallucination is simple and unformed followed by pat-
terns, people, animals, faces, landscapes and objects [39, 48].
Methodological issues
Charles Bonnet Syndrome differs from the other conditions
reviewed above in that, by definition, it is not associated
with hallucinations in other modalities [49] or progressive
cognitive decline [50]. However, unlike other studies, the
impact of visual loss on the visual cortex needs to be taken
into account. As yet there are no structural imaging studies
comparing patients with and without visual hallucinations
in eye disease.
Summary of imaging findings
Table 1 summarises the evidence presented above. Oc-
cipital atrophy is found in each clinical condition within
sub-regions of visual association cortex in the lateral,
dorsal and ventral occipital lobe. It remains unclear whe-
ther the occipital cortex is diffusely affected in all condi-
tions or whether the distribution of atrophy varies from one
condition to another. Similarly, there is insufficient detail
to specify whether the primary visual cortex is affected in
each condition. Notable exceptions to the finding of oc-
cipital atrophy are Meppelink et al. [21] in Parkinson’s
disease and Middlekoop et al. [28] in Dementia with Lewy
bodies and Alzheimer’s disease. As noted above, the
Middlekoop et al. finding is based on small numbers. The
negative finding reported by Meppelink et al. may relate to
a conservative whole-brain analysis of the data. Although
an absence of difference is also reported in a region of
interest analysis of the left fusiform gyrus, no mention is
made of whether this is also the case in other occipital
regions.
The parietal and ventral temporal lobe also contains re-
gions considered part of the extended visual system. As in
the occipital lobe, parietal regions were found atrophied in
patients with visual hallucinations across all conditions, in
particular the inferior parietal lobe. Atrophy was identified
here in Parkinson’s disease, Dementia with Lewy bodies and
Alzheimer’s disease literature and, although not specifically
mentioned in the text, the figure illustrating visual asso-
ciation cortex atrophy in first episode psychosis includes the
region [7], with evidence of changes in gyrification in
schizophrenia [43]. Atrophy is also reported in the superior
parietal lobule, but there is insufficient evidence to deter-
mine whether this varies across conditions. The ventral ex-
tension of the visual system into the temporal lobe is affected
in Parkinson’s disease in some studies but was reported as
unaffected in the left fusiform gyrus by Meppelink et al.
[21]. It was not identified in the study of Dementia with
Lewy bodies by Sanchez-Castaneda et al. [20] using a
conservative whole-brain analysis and fell outside the region
of interest studied by Middlekoop et al. [28]. Ventral tem-
poral regions of interest were not associated with increases
in hallucinations of unspecified modality in Alzheimer’s
disease [38] and were not mentioned or illustrated in the first
episode psychosis study [7]. It therefore remains unclear
whether ventral temporal cortex is implicated in visual
hallucinations across all conditions.
Regions of frontal atrophy were identified in Parkin-
son’s disease and Dementia with Lewy bodies. The regions
cluster around areas linked to attentional networks whose
dysregulation has been proposed as a mechanism for visual
hallucinations [51], overlapping those involved in eye
movements (medial and lateral frontal eye fields in the pre-
J Neurol (2015) 262:1780–1790 1785
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central cortex, supplementary frontal eye fields in the
middle portion of the cingulate gyrus [52] ). Frontal regions
of interest were not associated with hallucinations of un-
specified modality in Alzheimer’s disease [38] and were
not mentioned or illustrated in the first episode psychosis
study [7]. Like ventral temporal regions, it remains unclear
whether frontal regions are implicated in all conditions
associated with visual hallucinations.
Changes in the hippocampus have been noted in both
Parkinson’s disease and schizophrenia but in opposite di-
rections. In schizophrenia, relative hypertrophy was found
compared to patients with auditory hallucinations (visu-
al ? auditory hallucinator[ auditory hallucinator). In
Parkinson’s disease, hippocampal atrophy was found (vi-
sual hallucinator\ non-hallucinator). The region has not
been reported as a separate region of interest in the Alz-
heimer’s disease or Dementia with Lewy bodies literature
so it remains unclear whether changes in hippocampal
volume also occur in these conditions.
The thalamus was not reported as affected in any of
the studies reviewed using a whole-brain analysis or in-
cluded as a separate region of interest. It was noted as an
area of atrophy at 2–3 year follow-up in patients with
Parkinson’s disease and visual hallucinations, which was
not found to the same degree in Parkinson’s disease pa-
tients without visual hallucinations [19]. It was also found
in patients with Dementia with Lewy bodies compared to
controls [30].
Discussion
Our review set out to examine whether the same neuro-
physiological mechanism predisposes to visual hallucina-
tions in all conditions by comparing the distribution of
cortical changes. To date, no imaging studies have investi-
gated visual hallucinations from a trans-diagnostic per-
spective, necessitating a comparison of studies using very
different methodological approaches. Despite this limita-
tion, patterns of cortical change common to different clinical
conditions seem to emerge. We discuss below what the
findings reveal about the pathophysiology of susceptibility to
visual hallucinations and the wider clinical significance of
the findings for the development of effective treatments.
Table 1 Cortical changes associated with visual hallucinations
Brain region Clinical condition
Schizophrenia Alzheimer’s disease Dementia with Lewy
bodies and PCA
Parkinson’s disease and
Parkinson’s disease
dementia
Occipital lobe
Primary visual cortex Atrophy [30, 32] Atrophy [17, 22]
Secondary visual cortex Atrophy [7]a Atrophy [32] Atrophy [17, 22, 23]
Gross occipital lobe Atrophy [37]
Parietal lobe
Superior Lobule Reduced Gyri [43] Atrophy [32] Atrophy [17]
Inferior Lobule Atrophy [7]a Atrophy [38] Atrophy [19, 22, 23]
Temporal lobe
Hippocampus Atrophy [31]a
CA1 Hypertrophy [42]
Subiculum Hypertrophy [42]
Head Atrophy [18]
Middle fusiform gyri Atrophy [22, 23]
Frontal lobe
Pre-central cortex Atrophy [20] Atrophy [19, 23]
Dorsolateral prefrontal cortex Atrophy [20] Atrophy [22, 24]
Frontal pole Atrophy [19, 20, 22, 24]
Middle Cingulate cortex Atrophy [23]
Subcortical structures
Thalamus Atrophy [30] Atrophy [19]
Basal ganglia Atrophy [30]
a Comparison with healthy controls
1786 J Neurol (2015) 262:1780–1790
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Methodological considerations
It is perhaps surprising that a degree of consistency has been
found between studies of different conditions, given that
many factors will contribute to their variability. Beyond
technical details of the scanners or image processing and
segmentation techniques used, there are important differ-
ences in analysis strategy. These include the choice of
control for a given condition, the covariates accounted for in
the analysis (for example the presence and severity of de-
mentia, age and additional symptoms such as hallucinations
in other modalities, delusions, movement disorder, fluc-
tuation in cognition, etc.), whether the study investigates
pre-specified regions or the whole brain and whether regions
associated with visual hallucinations are identified by a
categorical approach (comparing groups with and without
visual hallucinations) or by correlating cortical volume with
the severity or frequency of hallucinations. Furthermore,
studies vary in the way hallucination status is defined. Most
use the response to a questionnaire item or set of items
within widely used instruments [e.g. neuropsychiatry in-
ventory (NPI), positive and negative syndrome scale
(PANSS), scale of assessment of positive symptoms
(SAPS), unified Parkinson’s disease rating scale (UPDRS)]
or structured clinical interviews. As such, the time window
of what defines visual hallucination or non-hallucination
status may vary between studies, ranging from occurrence in
the preceding weeks to the entire course of the illness.
Similarly, a distinction may or may not be drawn between
visual hallucinations and other visual phenomena such as
illusions/pareidolia that are associated with hallucination
susceptibility [53]. Such methodological differences make it
difficult to draw firm conclusions about differences in pat-
terns of atrophy between conditions but add to the likelihood
that any similarities identified are robust and valid.
The cortical signature of visual hallucination
susceptibility
de Morsier argued that all visual hallucinations were linked
to the visual thalamo-cortical system. As might be predicted
by this account, changes in visual cortex were associated
with visual hallucination susceptibility in all conditions. The
parietal lobe, a region de Morsier held of particular sig-
nificance because of its connections to the pulvinar, was also
implicated. A key piece of missing evidence is whether
these cortical regions are also affected in patients with
Charles Bonnet Syndrome which, if correct, would add
support to de Morsier’s claim. What de Morsier had not
predicted is that regions outside the visual thalamo-cortical
system in the frontal lobe and hippocampus are also linked
to visual hallucinations. Current models of visual halluci-
nations in Parkinson’s disease and Dementia with Lewy
bodies focus on abnormal interactions between top-down
attentional processing (derived from frontal systems) and
bottom-up visual perceptual processing (from occipital
systems) [51, 54]. The atrophy within frontal executive/at-
tentional regions and visual networks in Parkinson’s disease
and Dementia with Lewy bodies is consistent with this view.
However, there is an absence of evidence as to whether the
same areas are also implicated in Alzheimer disease,
schizophrenia and Charles Bonnet Syndrome. Similarly, the
hippocampus, although not playing a prominent role in
current theories of visual hallucinations, is easily accom-
modated based on its connectivity to the visual system [55]
and might account for hallucinations of familiar or re-
membered experience in Dementia with Lewy bodies,
Parkinson’s disease and schizophrenia. As for frontal re-
gions, it is unclear whether the hippocampus is affected in
all conditions.
The functional neurophysiology of aberrant cortical
activation
Functional imaging evidence of spontaneous visual cortical
activation at the time of a visual hallucination [5, 6] leaves
open the question of what causes it. The evidence reviewed
here suggests regions where spontaneous activations have
been identified are atrophied in patients susceptible to vi-
sual hallucinations. Atrophy is traditionally interpreted as
causing a deficit in function. However, if reflecting changes
in internal cortical architecture, for example, a relative loss
of intra-cortical inhibitory neurones, it could result in hy-
per-excitability. This may be restricted to the area of at-
rophy or be propagated to connected areas. Alternatively,
atrophy may result in a loss of output/function to another
part of the network resulting in a deficit of modulatory
control (cortical de-afferentation) and consequent excita-
tion and hyper-excitability within the area to which it
connects. These three conceptual mechanisms could apply
without detectable cortical atrophy or even with an increase
in cortical volume (see Fig. 2). Changes in white matter
might also result in cortical hyper-excitability and visual
hallucinations through related mechanisms [56] but have
not been included in the figure.
Our finding of occipital and parietal atrophy in patients
with visual hallucinations, irrespective of condition, is
likely to reflect mechanism B with regions of atrophy
marking local hyper-excitability. The distribution of hyper-
excitable cortex will define the type of visual hallucination
experienced by a given patient [5] and, if varying sys-
tematically across conditions, would account for variations
in hallucination content in different clinical contexts. In
contrast, the frontal regions found atrophied are unlikely to
be directly responsible for the content of visual hallucina-
tions. These areas are more likely to represent mechanism
J Neurol (2015) 262:1780–1790 1787
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C, reflecting loss of top-down control over visual cortices
or mechanism A, reflecting activty propagated across the
network from the frontal lobe. The hippocampal hyper-
trophy found in schizophrenia and atrophy found in
Parkinson’s disease might both reflect the same mechan-
ism: localised hyper-excitability (B), altered hippocampal
influence on visual cortex (C) or propagated activity from
hippocampus (A). Of note, the hippocampus showed
spontaneous increases in activity at the time of visual
hallucinations in a patient with schizophrenia [6].
Clinical implications
de Morsier recognised that visual hallucinations occurred in
a wide range of clinical conditions; however, the true extent
of their prevalence and associated clinical problems are only
recently appreciated. Visual hallucinations are associated
with poorer prognosis, cognitive decline, distress and the
move from independent living to a care setting in many of
the conditions reviewed. There is a need to better understand
how to treat the symptom and prevent such outcomes, but
there is a current lack of evidence. Understanding whether
the cortical changes predisposing to visual hallucinations are
the same or different across conditions will help design fu-
ture treatment trials. If the mechanism predisposing to visual
hallucinations is always the same, one treatment may be
effective for all clinical conditions. Alternatively, if there are
several distinct mechanisms that predispose to visual hal-
lucinations, a different type of treatment may be required for
each mechanism, with individualised combinations of
treatment for patients whose visual hallucinations are caused
by more than one mechanism.
Conclusion
de Morsier’s clinical intuition that visual hallucinations are
linked to aberrant activity within visual networks seems to
be correct. The evidence reviewed here points to occipital
and parietal atrophy in patients susceptible to visual hal-
lucinations, irrespective of clinical context. Whether fron-
tal and hippocampal regions are also included in this
Fig. 2 A summary of the theoretical mechanisms by which changes
in cortical volume within a region of interest (ROI) are linked to
increased cortical excitability and visual hallucinations (VH). a In-
creased excitatory output from region of interest to connecting area
results in visual hallucinations in connected area. The increased
output may be associated with atrophied (upper row), normal volume
(middle row) or increased volume (lower row) cortex. b Increased
excitation within the region of interest results in visual hallucinations.
The increased excitation may be associated with atrophied (upper
row), normal volume (middle row) or increased volume (lower row)
cortex. c Decreased output from region of interest to connecting area
(cortical de-afferentation) results in loss of control/modulation
leading to excitability and visual hallucinations in connected area.
The decreased output may be associated with atrophied (upper row),
normal volume (middle row) or increased volume (lower row) cortex
1788 J Neurol (2015) 262:1780–1790
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network or specific to a subset of conditions remains un-
clear. Like de Morsier, we continue to lack techniques to
determine whether all visual hallucinations share a com-
mon neurophysiology. However, the indirect evidence of
cortical changes predisposing to visual hallucinations re-
veals features common to all conditions that help inform
the ongoing search for effective treatment.
Acknowledgments This work was carried out as part of an ACF
training scheme within King’s College London (RC). This paper
summarises independent research funded by the National Institute for
Health Research (NIHR) under its Programme Grants for Applied
Research scheme (RP-PG-0610-10100 SHAPED, co-applicant
DHFF). The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the Department of Health.
Conflicts of interest None declared.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. de Morsier G (1930) Le Me´canisme des hallucinations. Ann
Me´dico-Psychologiques 88:365–389
2. Heuyer G (1950) G. G. de Cle´rambault. Ence´phale 39:413–439
3. de Morsier G (1936) Les automatismes visuels. (Hallucinations
visuelles re´trochiasmatiques). Schweizerische Medizinische
Wochenschrift 66:700–703
4. de Morsier G (1938) Les Hallucinations: e´tude Oto-neuro-oph-
talmologique. Rev Oto-Neuro-Ophtalmol 16:244–352
5. ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P,
Williams S (1998) The anatomy of conscious vision: an fMRI
study of visual hallucinations. Nat Neurosci 1:738–742
6. Oertel V, Rotarska-Jagiela A, van de Ven VG, Haenschel C,
Maurer K, Linden DE (2007) Visual hallucinations in
schizophrenia investigated with functional magnetic resonance
imaging. Psychiatr Res Neuroimaging 156:269–273
7. Jardri R, Thomas P, Delmaire C, Delion P, Pins D (2013) The
neurodynamic organization of modality-dependent hallucina-
tions. Cereb Cortex 23:1108–1117
8. Goetz CG, Vaughan CL, Goldman JG, Stebbins GT (2014) I
finally see what you see: Parkinson’s disease visual hallucina-
tions captured with functional neuroimaging. Mov Disord
29:115–117
9. Diederich NJ, Fenelon G, Stebbins G, Goetz CG (2009) Hallu-
cinations in Parkinson disease. Nat Rev Neurol 5:331–342
10. Goetz CG, Stebbins GT (1995) Mortality and hallucinations in
nursing home patients with advanced Parkinson’s disease. Neu-
rology 45:669–671
11. Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of
nursing home placement in Parkinson’s disease: a population-
based, prospective study. J Am Geriatr Soc 48:938–942
12. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C,
Lane R (2006) Effects of rivastigmine in patients with and
without visual hallucinations in dementia associated with
Parkinson’s disease. Mov Disord 21:1899–1907
13. Galvin JE, Pollack J, Morris JC (2006) Clinical phenotype of
Parkinson disease dementia. Neurology 67:1605–1611
14. Barnes J, David AS (2001) Visual hallucinations in Parkinson’s
disease: a review and phenomenological survey. J Neurol Neu-
rosurg Psychiatry 70:727–733
15. Ibarretxe-Bilbao N, Junque C, Marti MJ, Tolosa E (2011) Cere-
bral basis of visual hallucinations in Parkinson’s disease: struc-
tural and functional MRI studies. J Neurol Sci 310:79–81
16. Fe´nelon G, Mahieux F, Huon R, Zie´gler M (2000) Hallucinations
in Parkinson’s disease: prevalence phenomenology and risk fac-
tors. Brain 123:733–745
17. Ramirez-Ruiz B, Marti MJ, Tolosa E, Gimenez M, Bargallo N,
Valldeoriola F, Junque C (2007) Cerebral atrophy in Parkinson’s
disease patients with visual hallucinations. Eur J Neurol Off J Eur
Fed Neurol Soc 14:750–756
18. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, Marti MJ, Vall-
deoriola F, Bargallo N, Junque C (2008) Hippocampal head at-
rophy predominance in Parkinson’s disease with hallucinations
and with dementia. J Neurol 255:1324–1331
19. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, Marti MJ, Vall-
deoriola F, Bargallo N, Juanes S, Tolosa E (2010) Differential
progression of brain atrophy in Parkinson’s disease with and
without visual hallucinations. J Neurol Neurosurg Psychiatry
81:650–657
20. Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B, Campdelacreu J,
Gascon J, Falcon C, Calopa M, Jauma S, Juncadella M, Junque C
(2010) Frontal and associative visual areas related to visual hal-
lucinations in dementia with Lewy bodies and Parkinson’s dis-
ease with dementia. Mov Disord 25:615–622
21. Meppelink AM, de Jong BM, Teune LK, van Laar T (2011)
Regional cortical grey matter loss in Parkinson’s disease without
dementia is independent from visual hallucinations. Mov Disord
26:142–147
22. Watanabe H, Senda J, Kato S, Ito M, Atsuta N, Hara K, Tsuboi T,
Katsuno M, Nakamura T, Hirayama M, Adachi H, Naganawa S,
Sobue G (2013) Cortical and subcortical brain atrophy in Parkin-
son’s disease with visual hallucination. Mov Disord 28:1732–1736
23. Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D,
deToledo-Morrell L, Goetz CG (2014) Visuoperceptive region
atrophy independent of cognitive status in patients with Parkin-
son’s disease with hallucinations. Brain 137:849–859
24. Gama RL, Bruin VM, Tavora DG, Duran FL, Bittencourt L,
Tufik S (2014) Structural brain abnormalities in patients with
Parkinson’s disease with visual hallucinations: a comparative
voxel-based analysis. Brain Cogn 87:97–103
25. Macijauskiene J, Lesauskaite V (2012) Dementia with Lewy
bodies: the principles of diagnostics, treatment, and management.
Medicina (Kaunas) 48:1–8
26. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feld-
man H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D,
Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T,
Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E,
Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer
D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I,
Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA,
Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB,
Trojanowski JQ, Yamada M (2005) Diagnosis and management
of dementia with Lewy bodies: third report of the DLB Consor-
tium. Neurology 65:1863–1872
27. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-
Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gau-
thier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos
Machado J, O’Brien J, Playfer J, Reid W (2004) Dementia with
Lewy bodies. Lancet Neurol 3:19–28
28. Middelkoop HA, van der Flier WM, Burton EJ, Lloyd AJ, Paling
S, Barber R, Ballard C, McKeith IG, O’Brien JT (2001) Dementia
with Lewy bodies and AD are not associated with occipital lobe
atrophy on MRI. Neurology 57:2117–2120
J Neurol (2015) 262:1780–1790 1789
123
29. Beyer MK, Larsen JP, Aarsland D (2007) Gray matter atrophy in
Parkinson disease with dementia and dementia with Lewy bodies.
Neurology 69:747–754
30. Josephs KA, Whitwell JL, Boeve BF, Knopman DS, Tang-Wai
DF, Drubach DA, Jack CR Jr, Petersen RC (2006) Visual hal-
lucinations in posterior cortical atrophy. Arch Neurol
63:1427–1432
31. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ,
Smith GE, Knopman DS, Petersen RC, Benarroch EE, Josephs
KA, Jack CR Jr (2007) Focal atrophy in dementia with Lewy
bodies on MRI: a distinct pattern from Alzheimer’s disease. Brain
130:708–719
32. Delli Pizzi S, Franciotti R, Tartaro A, Caulo M, Thomas A,
Onofrj M, Bonanni L (2014) Structural alteration of the dorsal
visual network in DLB patients with visual hallucinations: a
cortical thickness MRI study. PLoS One 9:e86624
33. Burns A, Jacoby R, Levy R (1990) Psychiatric phenomena in
Alzheimer’s disease. II: disorders of perception. B J Psych
157:76–81
34. Hebert R, Dubois MF, Wolfson C, Chambers L, Cohen C
(2001) Factors associated with long-term institutionalization of
older people with dementia: data from the Canadian Study of
Health and Aging. J Gerontol Ser A Biol Sci Med Sci
56:M693–699
35. Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA (2014)
Psychosis in Alzheimer’s disease. Biol Psychiatry 75:542–552
36. Ballard C, McKeith I, Harrison R, O’Brien J, Thompson P,
Lowery K, Perry R, Ince P (1997) A detailed phenomenological
comparison of complex visual hallucinations in dementia with
Lewy bodies and Alzheimer’s disease. Int Psychogeriatr
9:381–388
37. Holroyd S, Shepherd ML, Downs JH 3rd (2000) Occipital atro-
phy is associated with visual hallucinations in Alzheimer’s dis-
ease. J Neuropsychiatry Clin Neurosci 12:25–28
38. Donovan NJ, Wadsworth LP, Lorius N, Locascio JJ, Rentz DM,
Johnson KA, Sperling RA, Marshall GA (2014) Regional cortical
thinning predicts worsening apathy and hallucinations across the
Alzheimer disease spectrum. Am J Geriatr Psychiatry
22:1168–1179
39. Waters F, Collerton D, ffytche DH, Jardri R, Pins D, Dudley R,
Blom JD, Mosimann UP, Eperjesi F, Ford S, Laroi F (2014)
Visual hallucinations in the psychosis spectrum and comparative
information from neurodegenerative disorders and eye disease.
Schizophr Bull 40(Suppl 4):S233–245
40. Frieske DA, Wilson WP (1966) Formal qualities of hallucina-
tions: a comparitive study of the visual hallucinations in patients
with schizophrenic, organic and affective psychosis. In: Hoch PH,
Zubin J (eds) Psychopathology of Schizophrenia. Grune and
Stratton, New York, pp 49–62
41. McCabe MS, Fowler RC, Cadoret RJ, Winokur G (1972)
Symptom differences in schizophrenia with good and poor
prognosis. Am J Psychiatry 128:1239–1243
42. Amad A, Cachia A, Gorwood P, Pins D, Delmaire C, Rolland B,
Mondino M, Thomas P, Jardri R (2014) The multimodal con-
nectivity of the hippocampal complex in auditory and visual
hallucinations. Mol Psychiatry 19:184–191
43. Cachia A, Amad A, Brunelin J, Krebs MO, Plaze M, Thomas P,
Jardri R (2014) Deviations in cortex sulcation associated with
visual hallucinations in schizophrenia. Mol Psychiatry. doi:10.
1038/mp.2014.140
44. ffytche DH (2005) Visual hallucinations and the Charles Bonnet
Syndrome. Curr Psychiatr Reports 7:168–179
45. ffytche DH (2009) Visual hallucinations in eye disease. Curr
Opin Neurol 22:28–35
46. Tan CS, Lim VS, Ho DY, Yeo E, Ng BY, Au Eong KG (2004)
Charles Bonnet syndrome in Asian patients in a tertiary oph-
thalmic centre. Br J Ophthalmol 88:1325–1329
47. Menon GJ (2005) Complex visual hallucinations in the visually
impaired: a structured history-taking approach. Arch Ophthalmol
123:349–355
48. ffytche DH, Howard RJ (1999) The perceptual consequences of
visual loss: positive pathologies of vision. Brain 122:1247–1260
49. ffytche DH (2007) Visual hallucinatory syndromes: past, present,
and future. Dialog Clin Neurosci 9:173–189
50. Holroyd S, Rabins PV (1996) A three year follow-up study of
visual hallucinations in patients with macular degeneration.
J Nerv Ment Dis 184:188–189
51. Shine JM, Halliday GM, Naismith SL, Lewis SJ (2011) Visual
misperceptions and hallucinations in Parkinson’s disease: dys-
function of attentional control networks? Mov Disord
26:2154–2159
52. Ettinger U, ffytche DH, Kumari V, Kathmann N, Reuter B, Ze-
laya F, Williams SC (2008) Decomposing the neural correlates of
antisaccade eye movements using event-related FMRI. Cereb
Cortex 18:1148–1159
53. Uchiyama M, Nishio Y, Yokoi K, Hirayama K, Imamura T,
Shimomura T, Mori E (2012) Pareidolias: complex visual illu-
sions in dementia with Lewy bodies. Brain 135:2458–2469
54. Collerton D, Perry E, McKeith I (2005) Why people see things
that are not there: a novel Perception and Attention Deficit model
for recurrent complex visual hallucinations. Behav Brain Sci
28:737-757; discussion 757-794
55. Catani M, Jones DK, Donato R, ffytche DH (2003) Occipito-
temporal connections in the human brain. Brain 126:2093–2107
56. ffytche DH (2008) The hodology of hallucinations. Cortex
44:1067–1083
1790 J Neurol (2015) 262:1780–1790
123
